There is an error in [Table 2](#pone-0098836-t001){ref-type="table"}. The values for Plasma YKL-40 in the Multivariate PFS column and the Multivariate OS column are incorrect. The author has provided a corrected table here.
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###### Univariate and multivariate Cox analyses of PFS and OS in 510 patients with mCRC included in the Nordic VII Study according to pretreatment plasma YKL-40 and clinical parameters. All treatment groups are combined.

![](pone.0098836.t001){#pone-0098836-t001-1}

                                        Progression-free Survival   Overall Survival                                                                                               
  ------------------------------------ --------------------------- ------------------ ---------- ------ ------------ ---------- ------ ------------ ---------- ------ ------------ ----------
  Treatment arm B vs A                            0.95                 0.76--1.29        0.71     0.95   0.75--1.19     0.66     1.07   0.82--1.39    o.062     1.02   0.78--1.33     0.98
  Treatment arm C vs A                            1.22                 0.98--1.53        0.08     1.27   1.01--1.59    0.039     1.09   0.84--1.41     0.51     1.02   0.79--1.33     0.88
  Plasma YKL-40 (log)\*                           1.11                 1.03--1.20       0.006     0.99   0.90--1.08     0.75     1.18   1.06--1.32    0.002     1.12   1.01--1.25    0.033
  Age per 10 years                                0.94                 0.85--1.04        0.21     0.93   0.84--1.03     0.17     0.98   0.87--1.11     0.79     0.99   0.88--1.12     0.85
  Sex, Female vs. male                            1.09                 0.91--1.32        0.34     0.97   0.80--1.16     0.77     0.89   0.71--1.12     0.33     0.83   0.66--1.03    0.092
  *KRAS,* Mutant vs. WT                           1.16                 0.95--1.42        0.15     1.37   1.09--1.71    0.006     1.06   0.84--1.34     0.63     1.50   1.13--1.91    0.004
  *BRAF*, Mutant vs. WT                           1.99                 1.45--2.72      \<0.0001   2.56   1.81--3.63   \<0.0001   4.55   3.03--6.84   \<0.0001   4.71   3.21--6.93   \<0.0001
  No. of metastatic sites, \>1 vs. 1              1.42                 1.16--1.75       0.0007    1.40   1.14--1.72    0.001     1.51   1.19--1.92    0.0008    1.44   1.13--1.85    0.003
  WHO PS, ≥1 vs. 0                                1.65                 1.36--2.00      \<0.0001   1.40   1.13--1.73    0.002     1.98   1.59--2.46   \<0.0001   1.55   1.21--1.97    0.0003
  Serum CRP, Elevated vs. normal                  1.52                 1.25--1.84      \<0.0001   1.35   1.09--1.68    0.006     1.65   1.32--2.07   \<0.0001   1.31   1.03--1.69    0.030
  Serum CEA, Elevated vs. normal                  1.64                 1.27--2.10      \<0.0001   1.62   1.24--2.12    0.0005    1.90   1.40--2.58   \<0.0001   1.94   1.39--2.70   \<0.0001

HR  =  Hazard ratio. CI  =  Confidence interval. \*Plasma YKL-40 was included as a log transformed continuous variable.

There are also several errors in the third sentence of the "Changes in plasma YKL-40 and serum CEA during treatment and efficacy" section of the Results, including an incorrect P-value for the high-serum CEA. The correct sentence is: In contrast, short PFS was not associated with high plasma YKL-40 (continuous variable; HR  =  1.06; 95% CI 0.96-1.17; P  =  0.28) but with high serum CEA (HR  =  1.08; 95% CI 1.03-1.13; P  =  0.0026).
